Stay updated with breaking news from A 1726. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NeuroBo Pharmaceuticals, Inc. (NRBO) announced on Thursday that the FDA has approved its Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist.
Stock of NeuroBo Pharmaceuticals, Inc. (NRBO) gained 48 percent on Thursday after the FDA approved the company's Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist.
NeuroBo Pharmaceuticals, Inc. (NRBO), a clinical-stage biotechnology company, Thursday said it has submitted Investigational New Drug or IND application to FDA, regarding Phase 1 clinical trial of DA-1726 for the treatment of obesity.